p53 and BCL-2 as Prognostic Markers in Endometrial Carcinoma

Abstract

The objective of this study was to verify the frequency of p53 and BCL-2 immunohistochemical expression in patients with endometrial carcinoma and to correlate it with histological factors (histological type, tumor grade, depth of myometrial invasion, lymph node involvement and surgical staging) and survival. Forty-eight patients with endometrial carcinoma who were submitted to primary surgical treatment were assessed. p53 and BCL-2 immunohistochemical expression was determined using paraffin blocks containing the tumor area. p53 and BCL-2 expression was detected in 39.6% and 58.3% of the tumors, respectively. No significant difference was found regarding the frequency of p53 expression when analyzing histological type (33.3% in endometrioid tumors, 58.3% in non-endometrioid tumors; p = 0.176), depth of myometrial invasion (p = 0.632) and surgical staging (I-11.1%, II-66.7%, III-57.1%; p = 0.061). p53 expression was significantly more frequent in undifferentiated tumors (p = 0.007) and in those showing lymph node involvement (p = 0.030). Univariate analysis showed a positive association with death (RR, 3.358; CI, 1.386-8.134; p = 0.005) and short-term survival. The present study did not reveal any correlation between BCL-2 expression and histopathologic markers or survival. In conclusion, this study showed that p53 expression is directly correlated with undifferentiated tumors, lymph-node involvement and risk of death. On the other hand, BCL-2 expression was not correlated with any known histological factors.

Establishment of a nine‐gene prognostic model for predicting overall survival of patients with endometrial carcinoma

“…Among them, partial genes have been previously reported to be associated with EC prognosis, such as TP53 23, 24, PIK3CA 25, CDKN2A 26, 27, and PTEN 17. By performing KEGG enrichment analysis (Fig.…”

The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer

“…They are aggressive and occur in a distinct biological environment. Gene mutation and P53 protein accumulation are often found in type II lesions [10,12,13].…”

“…Approximately one in three endometrial cancers have abnormalities of P53 by immunohistochemistry [7,[14][15][16][17]. A number of studies have shown that both P53 overexpression and mutation are associated with poor prognosis [9,10,14,15,17]. It is worth noting that earlier grade 3 endometrioid carcinomas were classified as type II tumors.…”

“…Several publications have regarded the TP53 and the BCL-2 genes as possible markers of endometrial cancer aggressiveness [9][10][11]. Some 20-50% of endometrial carcinoma cases show abnormal P53 expression.…”

“…The expression of P53, as seen in immunohistochemical analysis, seems to be related to undifferentiated, aggressive tumors, with a poor prognosis [6]. BCL-2 expression is rela- www.fhc.viamedica.pl tively high in the normal endometrium, decreases in endometrial cancer and has been related to well-differentiated endometrial tumors, early-stage disease and diseases with a good prognosis [9,10].…”